TRVI - CIK 0001563880
The table below shows Trevi Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$42.09M | -$38.26M | -$31.71M | -$28.18M | -$28.95M | -$29.00M |
| Capital expenditure | $12.00K | $35.00K | $137.00K | $159.00K | - | $32.00K |
| Investing cash flow | -$94.11M | -$21.53M | $59.43M | -$107.37M | - | -$32.00K |
| Dividends paid | - | - | - | - | - |
Trevi Therapeutics, Inc. reported operating cash flow of -$42.09M for fiscal year 2025. That is down 10.0% from -$38.26M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$18.29M (FY 2018) to -$42.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $121.01M | $61.48M | -$7.91M | $111.31M | $20.77M | $16.72M |